SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer

To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.

Trial Details

NCT ID
NCT06476093
Phase
NA
Sponsor
The First People's Hospital of Lianyungang
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Anlotinib hydrochloride
Locations (sample)
  • Lianyungang, Jiangsu, China|34.59845,119.21556

Key Eligibility Criteria

  • Patients voluntarily participate in this study, sign informed consent, and demonstrate good compliance.
  • Patients with histologically or pathologically confirmed EGFR wild-type and EGFR mutant non-small cell lung cancer resistant to treatment.
  • The number of brain metastases is ≤ 5, and the patient has at least one assessable brain metastasis on imaging (RECIST 1.1). Additionally, the pati…
  • Age between 18-80 years, gender unspecified.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →